| Autor: |
Albayat S; Ministry of Public Health, Doha P.O. Box 42, Qatar., Almaslamani M; Communicable Disease Center, Hamad Medical Corporation, Doha P.O. Box 3050, Qatar., Alromaihi H; Ministry of Public Health, Doha P.O. Box 42, Qatar., Khogali H; Ministry of Public Health, Doha P.O. Box 42, Qatar., Mundodan J; Ministry of Public Health, Doha P.O. Box 42, Qatar., Joury J; Pfizer Gulf FZ LLC, Dubai P.O. Box 502749, United Arab Emirates., Haridy H; Pfizer Gulf FZ LLC, Dubai P.O. Box 502749, United Arab Emirates. |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccines [Vaccines (Basel)] 2023 May 06; Vol. 11 (5). Date of Electronic Publication: 2023 May 06. |
| DOI: |
10.3390/vaccines11050953 |
| Abstrakt: |
Widespread vaccination programs have been implemented in many countries to curtail the COVID-19 pandemic, with varying success and challenges. To better understand the successes and challenges of the global COVID-19 response in the face of emerging new variants and epidemiologic data, we discuss how Qatar engaged the healthcare sector, governmental bodies, and the populace to combat COVID-19, with a focus on the country's vaccination strategy. This narrative provides the history and timeline of the Qatar COVID-19 vaccination campaign; factors that helped the vaccination campaign and the transferable lessons learned are discussed. Details regarding how Qatar responded to challenges, such as vaccine hesitancy and mitigation of misinformation, are highlighted. Qatar was one of the first countries to procure the BNT162b2 (Comirnaty ® ; Pfizer-BioNTech, Pfizer Inc., New York, NY, USA) and mRNA-1273 (Spikevax ® ; Moderna, Cambridge, MA, USA) COVID-19 vaccines. A relatively high vaccination rate and low case mortality rate (0.14% as of 4 January 2023) was observed in Qatar compared with other countries (global case mortality rate, 1.02%). Learnings will be carried forward as a basis for addressing this evolving pandemic and any future national emergencies in Qatar. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
